Amgen Inc. Stock Soars on Successful Gastric Cancer Trial Results
Amgen Inc.’s stock price has surged due to positive news from its clinical trials, particularly the Phase 3 FORTITUDE-101 trial, which demonstrated the effectiveness of bemarituzumab in treating gastric cancer.
2 minutes to read








